Hematologic Neoplasm
10
2
2
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
14%
1 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (10)
HematoCare: Feasibility of a Survivorship Care Plan for Hematologic Cancer Patients Undergoing HSCT
Rutgers University Study of the Genetics of Blood Cancers
A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders
Factors Associated With Health-related Quality of Life and Social Participation of Patients With Multiple Myeloma and Their Caregivers
Cell Selection for Bone Marrow Transplants to Prevent Graft-Versus-Host-Disease
Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia
The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers
PENELOPE Observational Study: Prophylaxis and Treatment of Arterial and Venous Thromboembolism
Stem Cell (Modified Bone Marrow) Transplantation in HIV-Infected Patients With Blood Cancer
The Collection of Peripheral Blood Lymphocytes and Marrow Progenitor Cells From Normal Volunteers and Volunteers With Lymphoid or Hematologic Malignancies